High Response Rate in Myeloma With Novel CAR-T After Anti-BCMA Failure

(MedPage Today) -- More than 80% of patients whose multiple myeloma had progressed on standard chimeric antigen receptor (CAR) T-cell therapy responded to an investigational CAR T-cell agent, a small study from China showed.
Targeting the GPRC5D...